Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment outcomes compared to non-cannabis users. Clinicians should not withhold or delay evidence-based trauma-focused care for patients simply because they are using cannabis.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis clarifies whether cannabis use compromises the efficacy of evidence-based trauma-focused treatments in patients with co-occurring PTSD and substance use disorders, a clinically prevalent population where treatment guidance is limited. The findings directly inform clinical decision-making regarding patient selection and treatment planning for trauma-focused interventions in individuals with active cannabis use. Understanding these treatment outcomes is essential for optimizing therapeutic strategies and setting appropriate expectations in a patient population with substantial psychiatric comorbidity and elevated relapse risk.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis of individual patient data from Project Harmony offers valuable reassurance that trauma-focused treatments for PTSD remain efficacious even among patients with concurrent cannabis use and other substance use disorders, addressing a clinically relevant question about treatment generalizability. However, several important caveats warrant consideration: the analysis draws from only four RCTs within the larger dataset, cannabis use was likely measured as a binary variable rather than quantifying frequency or potency (which vary substantially in modern markets), and the trials themselves may have enrolled relatively motivated or treatment-engaged populations not fully representative of real-world complexity. The findings do not address whether cannabis use itself impedes PTSD recovery or whether active cannabis dependence requires concurrent intervention alongside trauma-focused therapy. For clinical practice, this work supports proceeding with evidence-based trauma-focused treatments in patients with comorbid cannabis and other substance use without presumptively withholding care, while maintaining realistic expectations that ongoing or heavy cannabis use may complicate treatment engagement and outcomes, and individualizing decisions